IN2014DN05787A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN05787A IN2014DN05787A IN5787DEN2014A IN2014DN05787A IN 2014DN05787 A IN2014DN05787 A IN 2014DN05787A IN 5787DEN2014 A IN5787DEN2014 A IN 5787DEN2014A IN 2014DN05787 A IN2014DN05787 A IN 2014DN05787A
- Authority
- IN
- India
- Prior art keywords
- angiotensin
- pharmaceutically acceptable
- composition
- disulfanediylbis
- aminobutane
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a pharmaceutical composition comprising in at least one pharmaceutically acceptable support or vehicle a combination of (3S 3S ) 4 4 disulfanediylbis(3 aminobutane 1 sulfonic acid) or a pharmaceutically acceptable salt or solvate thereof and a second active ingredient selected from the group consisting of angiotensin I converting enzyme inhibitors and angiotensin II receptor type I antagonists. Said composition isparticularly useful for the treatment of hypertension and related diseases and conditions.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11306735 | 2011-12-21 | ||
| PCT/EP2012/076607 WO2013092984A1 (en) | 2011-12-21 | 2012-12-21 | Combination of (3s,3s') 4,4'-disulfanediylbis(3-aminobutane 1-sulfonic acid) and a second antihypertensive agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN05787A true IN2014DN05787A (en) | 2015-05-15 |
Family
ID=47522577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN5787DEN2014 IN2014DN05787A (en) | 2011-12-21 | 2012-12-21 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US10959938B2 (en) |
| EP (1) | EP2793878B1 (en) |
| JP (2) | JP6212500B2 (en) |
| KR (1) | KR20140116879A (en) |
| CN (2) | CN109464432A (en) |
| AU (1) | AU2012356895B2 (en) |
| BR (1) | BR112014015276B1 (en) |
| CA (1) | CA2859704C (en) |
| CY (1) | CY1118711T1 (en) |
| DK (1) | DK2793878T3 (en) |
| EA (1) | EA028718B1 (en) |
| ES (1) | ES2619027T3 (en) |
| HK (1) | HK1203051A1 (en) |
| HR (1) | HRP20170267T1 (en) |
| HU (1) | HUE033403T2 (en) |
| IL (1) | IL233156B (en) |
| IN (1) | IN2014DN05787A (en) |
| LT (1) | LT2793878T (en) |
| MX (1) | MX345469B (en) |
| PL (1) | PL2793878T3 (en) |
| PT (1) | PT2793878T (en) |
| RS (1) | RS55774B1 (en) |
| SI (1) | SI2793878T1 (en) |
| WO (1) | WO2013092984A1 (en) |
| ZA (1) | ZA201405266B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2619027T3 (en) * | 2011-12-21 | 2017-06-22 | Quantum Genomics | Combination of (3S, 3S ') 4,4'-disulfanodiylbis (3-aminobutane 1-sulfonic acid) and a second antihypertensive agent |
| TW202207917A (en) * | 2020-05-06 | 2022-03-01 | 法商量子基因科技有限公司 | Pharmaceutical combination comprising a brain aminopeptidase inhibitor, a diuretic and a blocker of the systemic renin-angiotensin system |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2773712B1 (en) * | 1998-01-16 | 2000-06-02 | Inst Nat Sante Rech Med | PHARMACEUTICAL COMPOSITION CONTAINING AT LEAST ONE AMINOPEPTIDASE A INHIBITOR |
| PT1525188E (en) | 2002-07-16 | 2008-10-16 | Inst Nat Sante Rech Med | Novel derivatives of 4,4`-dithiobis-(3-aminobutane-1-sulphonates) and compositions containing same |
| FR2858617A1 (en) * | 2003-08-06 | 2005-02-11 | Inst Nat Sante Rech Med | NOVEL 4 ', 4'-DITHIOBIS- (3-AMINOBUTANE-1-SULFONATE-1-SULFONATES) DERIVATIVES AND COMPOSITIONS CONTAINING SAME |
| US20080014187A1 (en) * | 2006-07-15 | 2008-01-17 | Bryant Villeponteau | Compositions and Methods for Treating Hypertension and Inflammation |
| ES2619027T3 (en) * | 2011-12-21 | 2017-06-22 | Quantum Genomics | Combination of (3S, 3S ') 4,4'-disulfanodiylbis (3-aminobutane 1-sulfonic acid) and a second antihypertensive agent |
-
2012
- 2012-12-21 ES ES12812987.1T patent/ES2619027T3/en active Active
- 2012-12-21 RS RS20170225A patent/RS55774B1/en unknown
- 2012-12-21 WO PCT/EP2012/076607 patent/WO2013092984A1/en active Application Filing
- 2012-12-21 AU AU2012356895A patent/AU2012356895B2/en active Active
- 2012-12-21 SI SI201230901A patent/SI2793878T1/en unknown
- 2012-12-21 LT LTEP12812987.1T patent/LT2793878T/en unknown
- 2012-12-21 US US14/367,408 patent/US10959938B2/en active Active
- 2012-12-21 PL PL12812987T patent/PL2793878T3/en unknown
- 2012-12-21 PT PT128129871T patent/PT2793878T/en unknown
- 2012-12-21 DK DK12812987.1T patent/DK2793878T3/en active
- 2012-12-21 MX MX2014007547A patent/MX345469B/en active IP Right Grant
- 2012-12-21 HU HUE12812987A patent/HUE033403T2/en unknown
- 2012-12-21 JP JP2014548062A patent/JP6212500B2/en not_active Expired - Fee Related
- 2012-12-21 CN CN201810509836.2A patent/CN109464432A/en active Pending
- 2012-12-21 IN IN5787DEN2014 patent/IN2014DN05787A/en unknown
- 2012-12-21 EP EP12812987.1A patent/EP2793878B1/en active Active
- 2012-12-21 CN CN201280069935.4A patent/CN104220062B/en not_active Expired - Fee Related
- 2012-12-21 KR KR1020147020364A patent/KR20140116879A/en active Search and Examination
- 2012-12-21 BR BR112014015276-4A patent/BR112014015276B1/en not_active IP Right Cessation
- 2012-12-21 EA EA201400724A patent/EA028718B1/en unknown
- 2012-12-21 CA CA2859704A patent/CA2859704C/en active Active
-
2014
- 2014-06-16 IL IL233156A patent/IL233156B/en active IP Right Grant
- 2014-07-18 ZA ZA2014/05266A patent/ZA201405266B/en unknown
-
2015
- 2015-04-13 HK HK15103574.1A patent/HK1203051A1/en not_active IP Right Cessation
-
2017
- 2017-02-20 HR HRP20170267TT patent/HRP20170267T1/en unknown
- 2017-03-09 CY CY20171100303T patent/CY1118711T1/en unknown
- 2017-07-21 JP JP2017141918A patent/JP6726138B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201100691A1 (en) | ANTAGONISTS OF LYSOPHPATIDIC ACID RECEPTORS | |
| WO2009088414A3 (en) | Oral pharmaceutical dosage forms | |
| MX2013005533A (en) | Substituted amino bisphenyl pentanoic acid derivatives as nep inhibitors. | |
| WO2016004093A3 (en) | Therapeutic compositions including galectin-3 inhibitors and uses thereof | |
| EA201270467A1 (en) | POLYCYCLIC CONNECTIONS AS ANTAGONISTS OF LYSOPHOSPHATID ACID RECEPTORS | |
| MX2011011428A (en) | Sulfamoyl benzoic acid derivatives as trpm8 antagonists. | |
| WO2011041729A3 (en) | Compounds as lysophosphatidic acid receptor antagonists | |
| WO2011017350A3 (en) | Compounds as lysophosphatidic acid receptor antagonists | |
| EA201390821A1 (en) | ANTAGONISTS OF LYSOPHPATIDIC ACID RECEPTORS AND THEIR APPLICATION | |
| NO20073959L (en) | Quinazoline derivative, method of preparation and use thereof for inhibiting cancer cell growth | |
| WO2010141768A3 (en) | Polycyclic antagonists of lysophosphatidic acid receptors | |
| FR2906140B1 (en) | GALENIC FORM FOR TRANSMUCOSUS ADMINISTRATION OF ACTIVE INGREDIENTS | |
| CY1115556T1 (en) | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION THAT INCLUDES DAVIGATRAN | |
| WO2008129501A3 (en) | Pharmaceutical compositions of duloxetine | |
| JO3587B1 (en) | Oral dosage forms of bendamustine | |
| TN2014000060A1 (en) | Benzothiazolone compound | |
| WO2012085249A3 (en) | Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid | |
| MX2017010666A (en) | (2r,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-met hyloxazole-2-carbonyl)amino]pentanoic acid. | |
| IN2014DN05787A (en) | ||
| SG10201809506TA (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
| TR201803451T4 (en) | OLMESARTAN FORMULATIONS. | |
| WO2007110765A3 (en) | Processes for the preparation of octreotide | |
| EA201190282A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING TAMSULUS | |
| WO2011161223A3 (en) | Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts | |
| MY143949A (en) | An orally active thrombin inhibitor |